Healthcare and Medical Device

The companion diagnostics industry is experiencing remarkable growth, projected to soar from $7.5 billion in 2024 to $13.6 billion by 2029, at an impressive compound annual growth rate (CAGR) of 12.6%. This surge can be attributed to the increasing significance of personalized medicine, the rising prevalence of chronic diseases like cancer, and the growing adoption of targeted therapies. Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681 Personalized Medicine: The Driving Force The increasing awareness of the advantages of personalized medicine is a key driver propelling the utilization of companion diagnostics and genomics & proteomics technologies. These diagnostic tests analyze specific indications for particular drugs in individual patients, enabling healthcare providers to devise tailored treatment plans and minimize the risk of adverse events. The shift towards personalized medicine is reshaping healthcare practices, with a focus...

  According to a new report by MarketsandMarkets™ –   Companion Diagnostics Market   in terms of revenue was estimated to be worth $7.5 billion in 2024 and is poised to reach $13.6 billion by 2029, growing at a CAGR of 12.6% from 2024 to 2029. The global companion diagnostics market is poised for significant growth in the near future, driven by the increasing incidence of cancers worldwide. This rise in cancer cases is fueling the demand for more accurate and personalized treatment options. Companion diagnostics play a crucial role in this scenario by helping to select appropriate targeted therapies for patients based on their genetic makeup and likely response. This personalized approach is expected to improve treatment outcomes while reducing adverse reactions to unsuited medicines. Additionally, the approvals of many targeted oncology drugs, along with complementary companion diagnostics, by regulatory agencies are expected to further propel the market growth. Emerging...